2. Academic Validation
  3. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

  • Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329.
E Anders Kolb 1,  Richard Gorlick,  Stephen T Keir,  John M Maris,  Min H Kang,  C Patrick Reynolds,  Richard B Lock,  Hernan Carol,  Jianrong Wu,  Raushan T Kurmasheva,  Peter J Houghton,  Malcolm A Smith
Affiliations

Affiliation

  • 1 Nemours/A.I. duPont Hospital for Children, Wilmington, Delaware.
PMID: 25407467 DOI: 10.1002/pbc.25329
Abstract

BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in Cancer cells through disruption of the microtubule network. In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50 ) of 13.8 nM (range 5.4-25.2 nM). The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine. BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts. No objective responses were observed.

Keywords

developmental therapeutics; microtubule-binding agents; preclinical testing; vascular-disrupting agents.

Figures
Products